Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $122.28 | 7 | 77.7% |
| Education | $35.00 | 2 | 22.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Indivior Inc. | $67.74 | 4 | $0 (2024) |
| Hikma Pharmaceuticals USA | $35.00 | 2 | $0 (2022) |
| Genentech USA, Inc. | $22.94 | 1 | $0 (2020) |
| Braeburn Inc. | $19.75 | 1 | $0 (2024) |
| Alkermes, Inc. | $11.85 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87.49 | 5 | Indivior Inc. ($67.74) |
| 2022 | $35.00 | 2 | Hikma Pharmaceuticals USA ($35.00) |
| 2021 | $11.85 | 1 | Alkermes, Inc. ($11.85) |
| 2020 | $22.94 | 1 | Genentech USA, Inc. ($22.94) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: Opioid Use Disorder | ||||||
| 12/04/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: OUD | ||||||
| 11/22/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: OUD | ||||||
| 11/13/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: OUD | ||||||
| 08/28/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: OUD | ||||||
| 09/14/2022 | Hikma Pharmaceuticals USA | Kloxxado (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 09/14/2022 | Hikma Pharmaceuticals USA | Kloxxado (Drug) | Education | In-kind items and services | $14.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 07/20/2021 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $11.85 | General |
| Category: CNS | ||||||
| 02/21/2020 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Virology & Specialty Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 528 | 730 | $95,845 | $26,982 |
| 2022 | 12 | 727 | 1,003 | $128,410 | $43,418 |
| 2021 | 12 | 705 | 986 | $119,333 | $39,473 |
| 2020 | 14 | 684 | 909 | $114,014 | $28,780 |
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 182 | 204 | $45,875 | $12,578 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 111 | 116 | $27,870 | $7,580 | 27.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 28 | 28 | $6,720 | $2,181 | 32.5% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 42 | 45 | $3,600 | $1,825 | 50.7% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 30 | 60 | $3,000 | $973.20 | 32.4% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 22 | 22 | $1,760 | $761.64 | 43.3% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 25 | 26 | $1,300 | $421.20 | 32.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 11 | 11 | $1,855 | $265.21 | 14.3% |
| 69209 | Removal of impacted ear wax by washing | Office | 2023 | 11 | 13 | $585.00 | $153.88 | 26.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 15 | $600.00 | $144.62 | 24.1% |
| 81003 | Automated urinalysis test | Office | 2023 | 35 | 39 | $1,170 | $85.80 | 7.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 16 | 151 | $1,510 | $13.84 | 0.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 154 | 164 | $39,360 | $15,552 | 39.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 160 | 172 | $38,700 | $11,131 | 28.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $13,500 | $5,633 | 41.7% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 123 | 128 | $10,240 | $4,460 | 43.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 48 | 48 | $11,520 | $3,679 | 31.9% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 47 | 94 | $4,700 | $1,535 | 32.6% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 28 | 29 | $3,886 | $686.18 | 17.7% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 21 | 21 | $1,050 | $343.13 | 32.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 24 | 25 | $1,000 | $191.17 | 19.1% |
| 81003 | Automated urinalysis test | Office | 2022 | 41 | 44 | $1,320 | $97.42 | 7.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 12 | 12 | $924.00 | $96.26 | 10.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 24 | 221 | $2,210 | $14.15 | 0.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 217 | 238 | $53,530 | $15,793 | 29.5% |
About Dr. David Beane, MD
Dr. David Beane, MD is a Family Medicine healthcare provider based in Vienna, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1821097734.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Beane, MD has received a total of $157.28 in payments from pharmaceutical and medical device companies, with $87.49 received in 2024. These payments were reported across 9 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($122.28).
As a Medicare-enrolled provider, Beane has provided services to 2,644 Medicare beneficiaries, totaling 3,628 services with total Medicare billing of $138,653. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Other Specialties Family Medicine
- Location Vienna, WV
- Active Since 07/21/2005
- Last Updated 05/09/2024
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1821097734
Products in Payments
- SUBLOCADE (Drug) $67.74
- Kloxxado (Drug) $35.00
- Xofluza (Drug) $22.94
- BRIXADI (Drug) $19.75
- VIVITROL (Drug) $11.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Vienna
Zaid Khalil, M.d, M.D
Family Medicine — Payments: $18,527
Dr. Barbara Mackie, Md, MD
Family Medicine — Payments: $10,097
Dr. Daniel Fitzpatrick, D.o, D.O
Family Medicine — Payments: $8,014
Dr. Barnett Mennen, M.d, M.D
Family Medicine — Payments: $4,521
Ernest Miller, Do, DO
Family Medicine — Payments: $4,057
Dr. Daniel Merenstein, Md, MD
Family Medicine — Payments: $3,041